CL2023001930A1 - Stable coronavirus proteins and vaccine compositions thereof - Google Patents

Stable coronavirus proteins and vaccine compositions thereof

Info

Publication number
CL2023001930A1
CL2023001930A1 CL2023001930A CL2023001930A CL2023001930A1 CL 2023001930 A1 CL2023001930 A1 CL 2023001930A1 CL 2023001930 A CL2023001930 A CL 2023001930A CL 2023001930 A CL2023001930 A CL 2023001930A CL 2023001930 A1 CL2023001930 A1 CL 2023001930A1
Authority
CL
Chile
Prior art keywords
stable
coronavirus
vaccine compositions
proteins
mutated
Prior art date
Application number
CL2023001930A
Other languages
Spanish (es)
Inventor
Ellis Daniel
KING Neil
Bloom Jesse
Starr Tyler
Greaney Allison
Original Assignee
Univ Washington
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Fred Hutchinson Cancer Center filed Critical Univ Washington
Publication of CL2023001930A1 publication Critical patent/CL2023001930A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente se proporcionan composiciones y métodos que comprenden proteínas de espiga "S" del coronavirus mutadas o dominios de unión al receptor de las mismas que tienen un aumento del nivel de expresión, rendimiento y estabilidad en comparación con su correspondiente proteína de espiga del coronavirus nativa o de tipo salvaje en las mismas condiciones de expresión, cultivo o almacenamiento. Estas proteínas de espiga mutadas se pueden usar para generar una vacuna basada en proteínas contra uno o más coronavirus.Provided herein are compositions and methods comprising mutated coronavirus "S" spike proteins or receptor binding domains thereof that have an increased level of expression, performance and stability compared to their corresponding coronavirus spike protein. native or wild type under the same expression, cultivation or storage conditions. These mutated spike proteins can be used to generate a protein-based vaccine against one or more coronaviruses.

CL2023001930A 2020-12-31 2023-06-29 Stable coronavirus proteins and vaccine compositions thereof CL2023001930A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063132863P 2020-12-31 2020-12-31
US202163188651P 2021-05-14 2021-05-14

Publications (1)

Publication Number Publication Date
CL2023001930A1 true CL2023001930A1 (en) 2023-11-24

Family

ID=82260758

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001930A CL2023001930A1 (en) 2020-12-31 2023-06-29 Stable coronavirus proteins and vaccine compositions thereof

Country Status (9)

Country Link
EP (1) EP4271698A1 (en)
JP (1) JP2024502823A (en)
KR (1) KR20230135598A (en)
AU (1) AU2021415906A1 (en)
BR (1) BR112023013138A2 (en)
CA (1) CA3201697A1 (en)
CL (1) CL2023001930A1 (en)
CO (1) CO2023008898A2 (en)
WO (1) WO2022146484A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113150084B (en) * 2021-03-23 2023-03-21 江苏坤力生物制药有限责任公司 Nanocrystallized coronavirus antigen and application thereof

Also Published As

Publication number Publication date
BR112023013138A2 (en) 2023-10-31
CO2023008898A2 (en) 2023-09-29
EP4271698A1 (en) 2023-11-08
WO2022146484A1 (en) 2022-07-07
AU2021415906A1 (en) 2023-07-06
KR20230135598A (en) 2023-09-25
JP2024502823A (en) 2024-01-23
CA3201697A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
AR118465A1 (en) RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
CL2022002359A1 (en) Molecular Constructs for Downregulating Ga3 Oxidase Protein Expression and Related Methods (Application Divisional 2242-2020)
CO2020005645A2 (en) Trispecific proteins and methods of use
DOP2018000245A (en) GDF15 FUSION PROTEINS AND USES OF THESE
BR112018008766A2 (en) variants, compositions and methods and uses of the reduced factor viii cpg for the treatment of hemostasis disorders
AR101953A1 (en) FUSION PROTEINS, RECOMBINANT BACTERIA AND METHODS OF USE OF THE RECOMBINANT BACTERIA
MX2020010466A (en) Antibody-evading virus vectors.
EA202091352A1 (en) GENOTHERAPY OF MUCOPOLYSACCHARIDOSIS IIIB
BR112019003945A2 (en) ophthalmic compositions
EA201890516A1 (en) CLINICAL COMPOSITIONS
AR061294A1 (en) PLANTS WITH IMPROVED GROWTH CHARACTERISTICS AND METHOD TO PREPARE THEM
EA201790842A1 (en) CRY1DA1 PROTEINS WITH AMINO-ACID SEQUENCE OPTIONS, HAVING ANY ACTIVITY AGAINST CRASHBACK
CO2021014778A2 (en) Modified s1 subunit of coronavirus spike protein
ECSP17075380A (en) VARIANT III FUSIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-MESOTHELIN AND METHODS TO USE THE SAME
UY37863A (en) ADENOASOCIATED VIRUS (AAV) WITH MODIFIED PHOSPHOLIPASE DOMAIN
CO2023003453A2 (en) Coronavirus Immunogenic Fusion Proteins and Related Methods
CO2023008898A2 (en) Stable coronavirus proteins and vaccine compositions thereof
BR112021020391A2 (en) Engineered producer cell lines and methods for preparing and using them
CL2019003459A1 (en) Cell culture methods.
CO6241171A2 (en) MAPACHE POXVIRUS EXPRESSING PORCINE VIRUS GENES
SV2008002942A (en) ENZYMES FOR REDUCED IMMUNOLOGICAL STRESS
CL2023001816A1 (en) Modified parapoxvirus having increased immunogenicity
EA202191786A1 (en) PREPARATION CONTAINING VACCINE ADJUVANT
AR066068A1 (en) PLANT FABRIC WITH AN ALTERED CONTENT OF A FLAVONOID COMPONENT; METHOD TO OBTAIN AND USE
AR107261A1 (en) PESTIVIRUS MARK VACCINE